IPI/PD1 Sequential Studies: Update of locations

[Catherine Poole]

Patients enrolled in the study will be randomized to one of 3 treatment arms. Patients

randomized to Arm A will receive nivolumab every 2 weeks until disease progression.

Patients on Arm B will receive nivolumab combined with ipilimumab every 3 weeks for

4 doses followed by nivolumab alone every 3 weeks until disease progression. Patients

randomized to Arm C will receive ipilimumab monotherapy every 3 weeks for a total of

4 doses.

For study locations near you, please email me as the list is too extensive to post: cpoole@melanomainternational.org. You must be treatment naïve (no previous treatment)

[Author]

Posts